Dr. Secord on Determining the Management Strategy for Ovarian Cancer

Video

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses determining the management strategy for patients with ovarian cancer.

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses determining the management strategy for patients with ovarian cancer.

Both PARP inhibitors and bevacizumab (Avastin) are FDA approved for the treatment of patients with platinum-sensitive ovarian cancer. However, PARP inhibitors and bevacizumab are given is very differently. Bevacizumab is given in combination with chemotherapy and followed with a maintenance strategy. In contrast, the PARP inhibitors are given after a patient has already had platinum-based therapy and demonstrated a response. Regardless, it is up to the physician to determine what management strategy to utilize before the patient begins chemotherapy, says Secord.

It was thought that biomarkers, such as germline BRCA mutations, would help determine the management strategy in a rational manner, explains Second. However, when the NOVA trial was completed it became apparent that there was a benefit across all groups, but the benefits differed based on whether patients had a germline BRCA mutation, homologous recombination deficits, or were germline wild-type.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,